AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03827915 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Double sequential external defibrillation
Description: DSED is the process of using two defibrillators near simultaneously at their highest allowed energy setting and aims to treat refractory atrial fibrillation. The first set of pads is placed in the traditional anterolateral position and the second set can be either placed adjacent to the first set (antero-lateral) or in the antero-posterior position. Shocks are then delivered simultaneously or near simultaneously
Study NCT01640431 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumbar stabilization exercises
Description: The patients performed exercises for the transversus abdominis and lumbar multifidus muscles for an hour twice a week.
Study NCT00108108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCD122
Study NCT01429337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midostaurin
Description: Midostaurin 25 mg soft gelatin capsules (2 capsules). The midostaurin capsules will be administered orally with 240 mL of non-carbonated water in the morning (between 8-10 AM), and in the evening (after a 12 hour break) from Day 1 to Day 6. On Day 7, midostaurin will be administered in the morning only (between 8-10 AM).
Study NCT01429337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midostaurin
Description: Midostaurin 25 mg soft gelatin capsules (2 capsules). The midostaurin capsules will be administered orally with 240 mL of non-carbonated water in the morning (between 8-10 AM) on Day 1 only.
Study NCT02431260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB054329 Monotherapy
Description: Initial cohort dose of INCB054329 monotherapy at the protocol-specified starting dose in the treatment group A (TGA), with subsequent cohort escalations in the three treatment groups (TGA, TGB, and TGC) based on protocol-specific criteria
Study NCT04204876 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Magnet Resonance Imaging (MRI)
Description: MRI with and without Gadolinium contrast agent for the following vessels: thoracic aorta (ascending, arch, descending arch, left and right common carotic, subclavian, and vertebral artery)
Study NCT04204876 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PET/CT analysis
Description: Standard value uptake measurement (SUV) based on quantitative score normalized to liver (SUV vessel max/liver mean) at the following vessel regions: Carotid artery: common, internal, external; Subclavian artery; Axillary artery; Vertebral artery; Thoracic Aorta; Abdominal Aorta; Common femoral artery; Deep femoral artery; Popliteal artery
Study NCT02227940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceritinib
Description: Given PO
Study NCT02380989 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01275586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasigna
Description: Following enrollment each subject will initially receive Tasigna orally at 200 mg twice daily for two weeks. If tolerated, the dose will be increased to 300 mg twice daily after a minimum of two weeks and will be increase to a maximum dose of 400mg twice daily after an additional two weeks if tolerated.
Study NCT02227940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT02227940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study NCT02227940 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02227940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel Albumin-Stabilized Nanoparticle Formulation
Description: Given IV
Study NCT02227940 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01398917 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: plastic endoprosthesis
Description: one 10 Fr Plastic endoprosthesis or 2 7 Fr plastic endoprosthesis inserted through dominant stricture(s), to be extracted after 1-2 weeks
Study NCT01398917 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: balloon dilatation
Description: 4 cm 6 mm biliary dilatation balloon to be inflated for 2 minutes in dominant stricture(s)
Study NCT03068351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6870810
Description: RO6870810 will be administered subcutaneously (SC) at ascending-dose levels (from 0.30 milligrams/kilogram \[mg/kg\] to 0.65 mg/kg). In Cycle 1, RO6870810 will be given on Day 1 (omitted on Day 2) and then every day from Day 3 through to Day 15. Starting at Cycle 2, it will be given every day from Day 1 to Day 14 of each 21-day cycle. In the first combination therapy cohort RO6870810 will be administered at one dose-level below the maximum tolerated dose (MTD).
Study NCT03068351 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: daratumumab
Description: Daratumumab will be administered intravenously (IV) at a dose of 16 milligrams/kilogram (mg/kg) of body weight weekly for the first 8 weeks, every two weeks for the following 16 weeks, and every four weeks thereafter, until disease progression.
Study NCT04431674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Definity Suspension for Injection
Description: MRI-guided ultrasound-stimulated microbubble-treatment
Study NCT01644747 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial Direct Current Stimulation (tDCS) (Eldith DC NeuroConn Stimulator)
Description: After locating the left DLPFC, ttt with active anodal tDCS with a current of 2 mA or sham over the left DLPFC will be directed by 30-minute session. Treatment will occur 2 sessions per day during 5 days per week. Subjects will be monitored during tDCS for any side effects or adverse events.
Study NCT01644747 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial Direct Current Stimulation (tDCS) (Eldith DC NeuroConn Stimulator)
Description: After locating the left DLPFC, ttt with active anodal tDCS with a current of 2 mA or sham over the left DLPFC will be directed by 30-minute session. Treatment will occur 2 sessions per day during 5 days per week. Subjects will be monitored during tDCS for any side effects or adverse events.
Study NCT02091505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Study NCT01336400 — intervention group
Intervention type: OTHER
Intervention: single cell haplotyping
Description: We aim to collect single blastomeres from spare IVF embryos of 30 couples to optimize and test methods for single cell haplotyping. We aim to collect 20 and 10 couples coming to the fertility centre for FISH- or PCR-based PGD respectively. In both groups, at least 5 different indications for PGD will be collected. Per couple, we will perform 10 SNP-arrays: 2 for the couple donating the embryo, 4 for family members (often parents of the couple) and 4 for blastomeres since we aim to pick 2 cells from 2 embryos per couple. For five couples, 2 blastomeres of all available embryos will be aspirated to validate and optimize the phasing methods. Finally, for some embryos, all blastomeres will be picked to be able to prove the reproducibility of single cell haplotyping.
Study NCT03911102 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DaxibotulinumtoxinA for injection
Description: Intramuscular injection
Study NCT04458324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone Hydrochloride
Description: Subjects take 30 mg buspirone HCl twice a day for 6 months.
Study NCT04458324 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Buspirone Hydrochloride
Description: Subjects take 30 mg buspirone HCl twice a day for 6 months.
Study NCT04458324 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Buspirone placebo
Description: Subjects take a placebo tablet twice a day for 6 months.
Study NCT04458324 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buspirone placebo
Description: Subjects take a placebo tablet twice a day for 6 months.
Study NCT04458324 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noninvasive Ventilation (NIV)
Description: The ventilator will be set in spontaneous mode with a ramp to reach a minimal pressure of 12 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.
Study NCT04458324 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Noninvasive Ventilation (NIV)
Description: The ventilator will be set in spontaneous mode with a ramp to reach a minimal pressure of 12 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.
Study NCT04458324 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Non-invasive ventilation (NIV)
Description: The ventilator will be set in spontaneous mode with a ramp to reach a maximal pressure of 5 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.
Study NCT04458324 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham Non-invasive ventilation (NIV)
Description: The ventilator will be set in spontaneous mode with a ramp to reach a maximal pressure of 5 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.
Study NCT04458324 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation Row Training (FESRT)
Description: Subjects participate in a supervised exercise training program 2-3 times/week for 6 months using an adapted indoor rower and FES.
Study NCT04458324 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Functional Electrical Stimulation Row Training (FESRT)
Description: Subjects participate in a supervised exercise training program 2-3 times/week for 6 months using an adapted indoor rower and FES.
Study NCT04458324 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Functional Electrical Stimulation Row Training (FESRT)
Description: Subjects participate in a supervised exercise training program 2-3 times/week for 6 months using an adapted indoor rower and FES.
Study NCT04458324 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Functional Electrical Stimulation Row Training (FESRT)
Description: Subjects participate in a supervised exercise training program 2-3 times/week for 6 months using an adapted indoor rower and FES.
Study NCT04526821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bovine Lactoferrin
Description: Bovine Lactoferrin 600mg daily for 12 weeks (3 chewable tablets of 100mg , twice a day), for 12 weeks plus personal portection provided from the hospital.
Study NCT04526821 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Maltodextrin 600mg daily for 12 weeks (3 chewable tablets of 100mg, twice a day), for 12 weeks plus personal portection provided from the hospital.
Study NCT01686893 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal oxygen insufflation with a TNI 20 oxy device
Description: Nasal oxygen insufflation with a TNI 20 oxy device
Study NCT01686893 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Nasal Insufflation of oxygen
Description: Standard Nasal Insufflation of oxygen
Study NCT01965873 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enteral nutrition
Description: Same as arm description
Study NCT02131129 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: The stimulation sites will be the left and right DLPFC, defined as 5 cm anterior to the scalp positions at which the MTs were determined. Treatments will be delivered within the following stimulation parameters: 110% of MT, 20 Hz, 30 trains, 1.0 second per train, 20 pulses per train, inter-train interval of 30 seconds (600 pulses/hemisphere, for a total of 1200 pulses/session/day).~Ten sessions over a two week duration
Study NCT02359708 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical hand disinfection.
Description: Bacterial recolonization
Study NCT02131129 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Description: The stimulation sites will be the left and right DLPFC, defined as 5 cm anterior to the scalp positions at which the MTs were determined. Treatments will be delivered within the following stimulation parameters: 110% of MT, 20 Hz, 30 trains, 1.0 second per train, 20 pulses per train, inter-train interval of 30 seconds (600 pulses/hemisphere, for a total of 1200 pulses/session/day).~Ten sessions over a two week duration
Study NCT01712516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QVA149
Description: QVA149 was supplied in a capsule form in blister packs for use in the Novartis Concept1 SDDPI
Study NCT03031002 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure treatment for spider fear
Description: Two sessions (each session = 60 minutes) of in-vivo exposure treatment (including psychoeducation) with two different spiders. Exposures comprise a hierarchy of 7 steps, to be completed with both spiders.
Study NCT01646333 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Memory and Problem-Solving Intervention
Description: 8 weekly 1 hour sessions of memory compensation and problem-solving strategies
Study NCT01646333 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Therapy
Description: 8 weekly 1 hour sessions of non-directive supportive therapy.
Study NCT01712516 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QAB149
Description: QAB149 was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
Study NCT01712516 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NVA237
Description: NVA237 was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
Study NCT01712516 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
Study NCT00912119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epsilon-Aminocaproic Acid
Description: Group C (high dose) will receive a loading dose of EACA of 100 mg/kg over ten minutes followed by a continuous EACA infusion at 40 mg/kg/hr, which will be continued until the end of surgery.
Study NCT03386019 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lymphatic massage
Description: One certified physical therapist will perform the massage regimens and techniques adapting from Swedish massage such as effleurage and petrissage that will be used in the massage group. Participants will first lay down in prone position, and the massage leg will be supported on the therapist's leg or on pillows with legs being positioned at approximately 30 degrees of knee flexion. This can promote venous return of the lower legs and also keep the ankle plantar flexors in a relative low muscle tension position. After positioning, long strokes will be applied from the distal to proximal part of gastrocnemius with approximately 20 repetitions and then 20 repetitions of circular strokes would be applied at the popliteal fossa. Finally, therapist will knead around participant's Achilles tendon for 10 repetitions.6 The combination of the techniques mentioned above will repeat 3 times in each subject, and the total duration of massage will be approximately 5 minutes.
Study NCT03754439 — intervention group
Intervention type: BEHAVIORAL
Intervention: Physiological changes to noise and vibration exposure
Description: Physiological parameters (HR, RR, Sats, NIRS) will be observed during a period of stay on the neonatal unit (Inborn group) or during ambulance transportation (Transported group) whilst simultaneous measurement of noise and vibration exposure. Urine will be collected during the first 24, 48 and 72 hours post exposure for biochemical markers of brain injury (S100B) and stress (Cortisol)
Study NCT03269929 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music therapy
Description: Subjects listened to music for 30 minutes before undergoing brachytherapy with spinal anesthesia
Study NCT03269929 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Subjects received intravenous midazolam 0,02 mg/kgBW injection before undergoing brachytherapy with spinal anesthesia
Study NCT00308581 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol
Description: 400mg Certolizumab Pegol, Q4W, administered 4-weekly
Study NCT00308581 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol
Description: 400mg Certolizumab Pegol, Q2W, administered 2-weekly
Study NCT00308581 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo administered 4-weekly in Active 1
Study NCT02438475 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mynx Vascular Closure System
Description: MynxGrip is being used to seal femoral vein access sites while reducing times to hemostasis and ambulation in patients who have undergone diagnostic or interventional endovascular procedures utilizing a 5F, 6F or 7F procedural sheath.
Study NCT02438475 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Manual Compression
Description: manual pressure applied to your groin for approximately 5-10 minutes
Study NCT00899353 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega 3 Fatty Acid
Description: Omega 3 supplementation will be initiated at three 1250 mg capsules daily for the first month. If dose is well tolerated, it will be increased to six 1250 mg capsules daily for 30 days, and finally to nine 1250 mg capsules daily. Treatment period is 12 months.
Study NCT00494767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW869682
Description: GW869682 tablet with a dose strength of 250 mg will be available for subjects
Study NCT00494767 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GW869682
Description: GW869682 tablet with a dose strength of 250 mg will be available for subjects
Study NCT00494767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK189075
Description: GSK189075 tablet with a dose strength of 250 mg will be available for subjects
Study NCT03386019 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Static stretching
Description: For the static stretching group, participants will perform the standing gastrocnemius stretches. First, participant stands facing a wall and put the stretched leg behind the body. Physical therapist will ask the participant to slightly flex the front leg, and keep back leg extended with heel on the ground. Both toes will be positioned pointing forward. Participant will then be asked to lunge forward slowly until the calf muscles on the back leg feeling stretched. Participant will hold in this position for 60 seconds and repeat 3 times.
Study NCT03386019 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold water immersion
Description: In the cold-water immersion group, participant's lower leg will be put in a bucket filled with cold water for 10 minute. The temperature of the water will be kept in 11-15 degrees Celsius.52 The water level should reach participant's fibular head to ensure complete immersion of the lower leg.
Study NCT02388620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE011
Description: 400 mg
Study NCT00494767 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK189075
Description: GSK189075 tablet with a dose strength of 250 mg will be available for subjects
Study NCT00494767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK189075-Placebo
Description: Placebo tablets to match GSK189075 250 mg will be available for subjects
Study NCT00494767 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK189075-Placebo
Description: Placebo tablets to match GSK189075 250 mg will be available for subjects
Study NCT01501591 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Hydroxizine
Description: 25 mg orally, one time on two different days, 72 hours apart
Study NCT01501591 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Matching placebo once on two different days, 72 hours apart.
Study NCT01501591 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: hydroxyzine/placebo
Description: 25 mg hydroxyzine or placebo once on two different days, 72 hours apart
Study NCT00494767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW869682-Placebo
Description: Placebo tablets to match GW869682 250 mg will be available for subjects
Study NCT00494767 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GW869682-Placebo
Description: Placebo tablets to match GW869682 250 mg will be available for subjects
Study NCT01033149 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: N-acetylcysteine
Description: N-acetylcysteine, flexible dose 1200-2400mg/day
Study NCT03005184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg bid
Description: oral medication during run-in and washout period
Study NCT03005184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg bid
Description: oral medication
Study NCT04172883 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment arm
Description: All pts are implanted with rATP enabled devices prior to the study start , the only intervention in both arms is switching on rATP and in the treatment arm programming changes done to optimize the rATP sequence delivery of therapy and prevent the patient from going into permanent or persistent AF
Study NCT01579695 — intervention group
Intervention type: DRUG
Intervention: Tesamorelin for injection
Description: Daily 2 mg subcutaneous injections of Tesamorelin